Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 4/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | LEF1 | Q9UJU2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HRAS | P01112 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14879050 | 0.93 | LCK (0.43) | LCKCHEK2MAPTMAPK1ESR2 | |
| SCHEMBL6509939 | 0.93 | LEF1 (0.37) | LCKBRD4LEF1MAPTACHE | |
| SCHEMBL5561415 | 0.90 | LCK (0.39) | LCKCHEK2BRD4ESR2TOP2A | |
| SCHEMBL15233047 | 0.86 | LCK (0.43) | LCKBRD4MAPTMAPK1 | |
| SCHEMBL5560010 | 0.84 | MAPT (0.39) | LCKCHEK2BRD4LEF1MAPT | |
| SCHEMBL14879051 | 0.82 | LCK (0.48) | LCKCHEK2MAPTMAPK1ESR2 | |
| SCHEMBL6511063 | 0.82 | RHEB (0.41) | LCKBRD4LEF1 | |
| SCHEMBL19739259 | 0.77 | SMN1; SMN2 (0.41) | MAPT | |
| SCHEMBL14879048 | 0.77 | LCK (0.46) | LCKCHEK2MAPTMAPK1ESR2 | |
| SCHEMBL5561204 | 0.76 | RHEB (0.41) | LCKBRD4LEF1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524899-B2 | Oligopeptide containing fused 6-membered ring forming complexes with double stranded dna; complexes can be used for identification of specific dsDNA sequences, inhibiting gene transcription, therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific gene | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-09-03 | — | — | US | disclosed |
| EP-1599474-B1 | Heterocyclic oligomeric compounds for DNA recognition | CALIFORNIA INST OF TECHN (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-1599474-A4 | ALTERNATIVE HETEROCYCLES FOR DNA RECOGNITION | CALIFORNIA INST OF TECHN (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1599474-A2 | ALTERNATIVE HETEROCYCLES FOR DNA RECOGNITION | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050026174-A1 | Alternative heterocycles for DNA recognition | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2005-02-03 | — | — | US | disclosed |
| WO-2004078943-A2 | ALTERNATIVE HETEROCYCLES FOR DNA RECOGNITION | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026174-A1 | Alternative heterocycles for DNA recognition | DDB1, PCNA, DNA2 | LCK 3761/4885CHEK2 327/4885BRD4 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.